Cantor Fitzgerald Weighs in on ALX Oncology FY2025 Earnings

ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of ALX Oncology in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek forecasts that the company will post earnings per share of ($2.21) for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for ALX Oncology's current full-year earnings is ($2.76) per share.

Other research analysts have also issued research reports about the company. Jefferies Financial Group lowered ALX Oncology from a "buy" rating to a "hold" rating and dropped their target price for the company from $12.00 to $2.00 in a report on Thursday, December 19th. HC Wainwright reissued a "buy" rating and issued a $25.00 price objective on shares of ALX Oncology in a research note on Wednesday, December 18th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $8.50.

ALX Oncology Stock Performance

Shares of ALXO stock traded down $0.17 during trading hours on Thursday, hitting $1.63. The stock had a trading volume of 6,355,434 shares, compared to its average volume of 1,251,236. The stock's 50 day moving average is $1.61 and its 200 day moving average is $2.43. The firm has a market capitalization of $85.97 million, a PE ratio of -0.55 and a beta of 0.98. ALX Oncology has a twelve month low of $1.19 and a twelve month high of $17.83. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82.

Hedge Funds Weigh In On ALX Oncology

Large investors have recently bought and sold shares of the stock. SG Americas Securities LLC lifted its stake in shares of ALX Oncology by 33.6% in the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company's stock valued at $50,000 after purchasing an additional 6,888 shares in the last quarter. Hsbc Holdings PLC acquired a new position in ALX Oncology during the second quarter valued at approximately $63,000. GSA Capital Partners LLP purchased a new stake in ALX Oncology during the third quarter worth approximately $88,000. Barclays PLC raised its stake in shares of ALX Oncology by 243.6% in the 3rd quarter. Barclays PLC now owns 59,502 shares of the company's stock valued at $107,000 after acquiring an additional 42,185 shares during the period. Finally, AQR Capital Management LLC lifted its holdings in shares of ALX Oncology by 50.7% during the 2nd quarter. AQR Capital Management LLC now owns 18,079 shares of the company's stock valued at $109,000 after acquiring an additional 6,080 shares in the last quarter. Hedge funds and other institutional investors own 97.97% of the company's stock.

Insiders Place Their Bets

In other ALX Oncology news, Director Rekha Hemrajani bought 30,000 shares of the company's stock in a transaction that occurred on Monday, December 2nd. The stock was purchased at an average cost of $1.55 per share, for a total transaction of $46,500.00. Following the completion of the purchase, the director now owns 33,000 shares of the company's stock, valued at $51,150. This trade represents a 1,000.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 14,443 shares of company stock valued at $23,309 in the last ninety days. Insiders own 33.40% of the company's stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.